Given that more than 50% of Asian and 10–20% of European non-small cell lung cancer (NSCLC) patients harbored active EGFR mutant, such as deletion mutation in exon 19 (del19) and the point mutation in exon 21 (L858R), mutant EGFR has become a vital therapeutic target for NSCLC [1, 2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.